This is associated with enhanced phosphorylation of AKT and ERK upon VPA treatment of FLT3-ITD-expressing AML cells as it might be expected following translocation of FLT3-ITD to the cell membrane. The gene discussed is MAPK1; the disease is acute myeloid leukemia.